Evidence map›Paper›PMID 24786708›Full record

ArticleKidney international2015

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.

Mark E Molitch, Amanda I Adler, Allan Flyvbjerg, Robert G Nelson, Wing-Yee So, Christoph Wanner, Bertram L Kasiske, David C Wheeler, Dick de Zeeuw, Carl E Mogensen

Open access · bronzeAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 4 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 4 syntheses or guidelines pooled it, 257 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
    Trial
  7. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Fibroblast growth factor 23 and incident CKD in type 2 diabetes.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 6 countries.

Mark E MolitchDivision of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Amanda I AdlerInstitute of Metabolic Science, Addenbrooke's Hospitals, Cambridge, UK.
Allan FlyvbjergAarhus University, Aarhus C, Denmark.
Robert G NelsonNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA.
Wing-Yee SoDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
Christoph WannerUniversity Hospital of Würzburg, Würzburg, Germany.
Bertram L KasiskeHennepin County Medical Center, Minneapolis, Minnesota, USA.
David C WheelerUniversity College London, London, UK.
Dick de ZeeuwUniversity Medical Center Groningen, Groningen, The Netherlands.
Carl E MogensenAarhus University Hospital and Aarhus University, Aarhus, Denmark.
Aarhus University · DKAarhus University Hospital · DKAddenbrooke's Hospital · GBChinese University of Hong Kong · CNHennepin County Medical Center · USNational Institutes of Health · USNorthwestern University · USUniversitätsklinikum Würzburg · DEUniversity College London · GBUniversity Medical Center Groningen · NL

Funding

Epidemiology, Pathophysiology and Treatment of Diabetic NephropathyZIADK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 2009 to 2023
$10.1M
RENOPROTECTION IN TYPE 2 DIABETES MELLITUSZ01DK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 1995 to 2008
$637k
Intramural NIH HHS Z01 DK069062
6 · The paper itself

Abstract

The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout the world, due primarily to the increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced the proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), the sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in the management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of the renin-angiotensin-aldosterone system; and lipid management.

Indexed as

AlbuminuriaDiabetic NephropathiesDisease ProgressionHumansHyperglycemiaHypertension

Identifiers

PMID24786708
PMCPMC4214898
OpenAlexW2136160292

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.